{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:41:16Z","timestamp":1791218476642,"version":"4.1.0"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Drug Deliv."],"abstract":"<jats:p>Oral delivery of peptides and proteins has been pursued for over a century due to its noninvasive nature. Despite sustained innovation across multiple technological generations\u2014such as enteric coatings, enzyme inhibitors, permeation enhancers, nanoparticles, and ingestible devices\u2014most oral peptide programs have failed to achieve regulatory or commercial success. The recent approval of oral semaglutide has renewed enthusiasm but introduced a substantial risk of conceptual over-extrapolation. This review critically examines the pharmacokinetic, pharmacodynamic, regulatory, and economic foundations of oral peptide delivery. Three recurrent failure modes explain the historical record: (1) exposure infeasibility when low bioavailability combines with short elimination half-life, preventing accumulation regardless of formulation sophistication; (2) variability-driven regulatory failure when coefficients of variation exceed thresholds compatible with bioequivalence requirements; and (3) dose escalation leading to gastrointestinal toxicity and prohibitive manufacturing costs before therapeutic efficacy is achieved. Oral semaglutide is analyzed as a boundary case rather than a platform validation. Its success reflects a rare alignment of properties: an exceptionally long half-life (\u223c168\u00a0h), high potency, wide therapeutic window, and time-integrated pharmacodynamics that accommodate low and variable absorption. Most peptides lack this constellation. Oral octreotide, approved under restricted maintenance-only labeling, is another boundary case that illustrates these constraints. Emerging macrocyclic peptides (MK-0616, JNJ-77242113) and small molecule GLP-1 agonists (orforglipron) may reshape the competitive landscape. To prevent predictable failure, this review proposes a negative-selection framework that identifies peptides unsuitable for classical oral delivery at an early stage. For excluded molecules, a route-triage strategy directs candidates toward pulmonary, nasal, buccal, or long-acting injectable delivery. Device-mediated swallowed injection systems differ from oral absorption and are evaluated as combination products governed by device reliability rather than pharmacokinetic enhancement. The fundamental conclusion is that the success of oral delivery depends on molecular pharmacology, not on formulation technology. Oral delivery should be pursued when pharmacology permits and abandoned when it does not\u2014a prerequisite for sustainable advancement in the field.<\/jats:p>","DOI":"10.3389\/fddev.2026.1776167","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T06:37:36Z","timestamp":1773988656000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Oral delivery of peptides and proteins: pharmacokinetic boundaries, negative selection, and route triage"],"prefix":"10.3389","volume":"6","author":[{"given":"Sarfaraz K.","family":"Niazi","sequence":"first","affiliation":[{"name":"College of Pharmacy, University of Illinois","place":["Chicago, IL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1126\/science.aau2277","article-title":"An ingestible self-orienting system for oral delivery of macromolecules","volume":"363","author":"Abramson","year":"2019","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e10143","DOI":"10.1002\/btm2.10143","article-title":"Nanoparticles in the clinic: an update","volume":"4","author":"Anselmo","year":"2019","journal-title":"Bioeng. Transl. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1177\/193229680900300322","article-title":"Oral insulin: the rationale for this approach and current developments","volume":"3","author":"Arbit","year":"2009","journal-title":"J. Diabetes Sci. Technol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"key":"B5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41586-024-08202-5","article-title":"Cephalopod-inspired jetting devices for gastrointestinal drug delivery","volume":"636","author":"Arrick","year":"2024","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/jne.12154","article-title":"Oxytocin: its mechanism of action and receptor signalling in the myometrium","volume":"26","author":"Arrowsmith","year":"2014","journal-title":"J. Neuroendocrinol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1208\/s12248-011-9307-4","article-title":"Absorption enhancers: applications and advances","volume":"14","author":"Aungst","year":"2012","journal-title":"AAPS J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.jacc.2023.02.018","article-title":"Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616","volume":"81","author":"Ballantyne","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"B9","volume-title":"The discovery of insulin","author":"Bliss","year":"1982"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.addr.2020.05.007","article-title":"Systemic delivery of peptides by the oral route: formulation and medicinal chemistry approaches","volume":"157","author":"Brayden","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B62","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1177\/0022034513500306","article-title":"Advances in the regulation of osteoclasts and osteoclast functions","volume":"92","author":"Boyce","year":"2013","journal-title":"J. Dent. Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"eaar7047","DOI":"10.1126\/scitranslmed.aar7047","article-title":"Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist","volume":"10","author":"Buckley","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11095-014-1485-1","article-title":"Enhancing the buccal mucosal delivery of peptide and protein therapeutics","volume":"32","author":"Caon","year":"2015","journal-title":"Pharm. Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.2337\/db08-1084","article-title":"The barrier of hypoglycemia in diabetes","volume":"57","author":"Cryer","year":"2008","journal-title":"Diabetes"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes","volume":"318","author":"Davies","year":"2017","journal-title":"JAMA"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2006.08.013","article-title":"Nanoparticles as potential oral delivery systems of proteins and vaccines","volume":"116","author":"Des Rieux","year":"2006","journal-title":"J. Control Release"},{"key":"B18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: new estimates of R&D costs","volume":"47","author":"DiMasi","year":"2016","journal-title":"J. Health Econ."},{"key":"B19","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"B20","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41573-019-0053-0","article-title":"Advances in oral peptide therapeutics","volume":"19","author":"Drucker","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"B21","volume-title":"Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind phase 3 trial","year":"2025"},{"key":"B22","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.addr.2011.12.009","article-title":"Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers","volume":"64","author":"Ensign","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B23","volume-title":"Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products - general considerations","year":"2003"},{"key":"B24","volume-title":"Clinical pharmacology review: Rybelsus (semaglutide) tablets. NDA 213051","year":"2019"},{"key":"B25","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/193229681300700228","article-title":"Oral insulin delivery: how far are we?","volume":"7","author":"Fonte","year":"2013","journal-title":"J. Diabetes Sci. Technol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discov. Today"},{"key":"B27","doi-asserted-by":"crossref","DOI":"10.1201\/b14095","volume-title":"Pharmacokinetics","author":"Gibaldi","year":"1982"},{"key":"B28","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s40262-018-0728-4","article-title":"Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide","volume":"58","author":"Granhall","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"B29","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S2213-8587(18)30372-3","article-title":"Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial","volume":"7","author":"Halberg","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2165\/00063030-200519030-00003","article-title":"Oral delivery of peptide drugs: barriers and developments","volume":"19","author":"Hamman","year":"2005","journal-title":"BioDrugs"},{"key":"B31","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1089\/152091502320798312","article-title":"Variability of insulin absorption and insulin action","volume":"4","author":"Heinemann","year":"2002","journal-title":"Diabetes Technol. Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3389\/fphar.2019.01328","article-title":"Advances in nanoparticulate drug delivery approaches for sublingual and buccal administration","volume":"10","author":"Hua","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.4155\/tde.15.75","article-title":"Mechanisms of absorption and elimination of drugs administered by inhalation","volume":"6","author":"Ibrahim","year":"2015","journal-title":"Ther. Deliv."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-025-02004-6","article-title":"Oromucosal films for peptide delivery: formulation strategies using permeation enhancers and polymers","author":"Karki","year":"2025","journal-title":"Drug Deliv. Transl. Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/jbmr.1","article-title":"Lessons learned from the development of oral calcitonin: the first peptide to be used orally in humans","volume":"25","author":"Karsdal","year":"2010","journal-title":"J. Bone Min. Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front. Endocrinol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1046\/j.1365-2125.2003.01892.x","article-title":"Pulmonary drug delivery. Part I: physiological factors affecting the therapeutic effectiveness of aerosolized medications","volume":"56","author":"Labiris","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1016\/j.bmc.2017.06.052","article-title":"Therapeutic peptides: historical perspectives, current development trends, and future directions","volume":"26","author":"Lau","year":"2018","journal-title":"Bioorg Med. Chem."},{"key":"B39","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J. Med. Chem."},{"key":"B40","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.addr.2016.07.007","article-title":"Oral absorption of peptides and nanoparticles across the human intestine: opportunities, limitations, and studies in human tissues","volume":"106","author":"Lundquist","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B41","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1615\/critrevtherdrugcarriersyst.v20.i23.30","article-title":"Emerging trends in oral delivery of peptide and protein drugs","volume":"20","author":"Mahato","year":"2003","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"key":"B42","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.drudis.2020.11.027","article-title":"Oral absorption enhancement: taking stock and looking forward","volume":"26","author":"Maher","year":"2021","journal-title":"Drug Discov. Today"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.addr.2009.09.006","article-title":"Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic","volume":"61","author":"Maher","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B44","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.addr.2016.06.005","article-title":"Intestinal permeation enhancers for oral peptide delivery","volume":"106","author":"Maher","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B45","doi-asserted-by":"publisher","first-page":"115572","DOI":"10.1016\/j.addr.2025.115572","article-title":"Devices to overcome the buccal mucosal barrier to administer therapeutic peptides","volume":"220","author":"Malhotra","year":"2025","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1210\/jc.2014-4113","article-title":"Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial","volume":"100","author":"Melmed","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B47","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.drudis.2006.08.005","article-title":"Is the oral route possible for peptide and protein drug delivery?","volume":"11","author":"Morishita","year":"2006","journal-title":"Drug Discov. Today"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.2147\/PPA.S463354","article-title":"Preference for a novel oral alternative to parenterally administered medications","volume":"18","author":"Myers","year":"2024","journal-title":"Patient Prefer Adherence"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.addr.2016.04.001","article-title":"Lipid-based nanocarriers for oral peptide delivery","volume":"106","author":"Niu","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.drudis.2022.02.001","article-title":"Emerging trends in pulmonary delivery of biopharmaceuticals","volume":"27","author":"Onoue","year":"2022","journal-title":"Drug Discov. Today"},{"key":"B51","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1513\/pats.200409-049TA","article-title":"The lungs as a portal of entry for systemic drug delivery","volume":"1","author":"Patton","year":"2004","journal-title":"Proc. Am. Thorac. Soc."},{"key":"B52","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2337\/dc15-1498","article-title":"Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: a randomized crossover noninferiority study","volume":"39","author":"Rickels","year":"2016","journal-title":"Diabetes Care"},{"key":"B53","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1615\/critreveukaryotgeneexpr.v15.i2.50","article-title":"The cellular and clinical parameters of anabolic therapy for osteoporosis","volume":"15","author":"Rosen","year":"2005","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"B54","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000192434","article-title":"The growth hormone cascade and its role in mammalian growth","volume":"71","author":"Rosenfeld","year":"2009","journal-title":"Horm. Res."},{"key":"B55","volume-title":"Clinical pharmacokinetics and pharmacodynamics: concepts and applications","author":"Rowland","year":"2011"},{"key":"B56","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s0090-4295(02)02396-8","article-title":"Eligard: leuprolide acetate in a novel sustained-release delivery system","volume":"61","author":"Sartor","year":"2003","journal-title":"Urology"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1111\/dom.13279","article-title":"Nasal glucagon: a viable alternative to treat insulin-induced hypoglycaemia in adults with type 1 diabetes","volume":"20","author":"Suico","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"B58","doi-asserted-by":"publisher","first-page":"e0181748","DOI":"10.1371\/journal.pone.0181748","article-title":"THPdb: database of FDA-approved peptide and protein therapeutics","volume":"12","author":"Usmani","year":"2017","journal-title":"PLoS One"},{"key":"B59","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/s1521-690x(03)00049-6","article-title":"Disorders of body water homeostasis","volume":"17","author":"Verbalis","year":"2003","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1056\/NEJMoa2500969","article-title":"Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4)","volume":"393","author":"Wharton","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1007\/s11095-007-9488-9","article-title":"Safe and effective permeation enhancers for oral drug delivery","volume":"25","author":"Whitehead","year":"2008","journal-title":"Pharm. Res."}],"container-title":["Frontiers in Drug Delivery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fddev.2026.1776167\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T06:37:38Z","timestamp":1773988658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fddev.2026.1776167\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":61,"alternative-id":["10.3389\/fddev.2026.1776167"],"URL":"https:\/\/doi.org\/10.3389\/fddev.2026.1776167","relation":{},"ISSN":["2674-0850"],"issn-type":[{"value":"2674-0850","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"article-number":"1776167"}}